Suppressing AP1 Factor Signaling in the Suprabasal Epidermis Produces a Keratoderma Phenotype

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2014 Jul 23

PMID 25050598

Citations 9

Authors

Ellen A Rorke

Gautam Adhikary

Christina A Young

Dennis R Roop

Richard L Eckert

Affiliations

Soon will be listed here.

Abstract

Keratodermas comprise a heterogeneous group of highly debilitating and painful disorders characterized by thickening of the skin with marked hyperkeratosis. Some of these diseases are caused by genetic mutation, whereas other forms are acquired in response to environmental factors. Our understanding of signaling changes that underlie these diseases is limited. In the present study, we describe a keratoderma phenotype in mice in response to suprabasal epidermis-specific inhibition of activator protein 1 transcription factor signaling. These mice develop a severe phenotype characterized by hyperplasia, hyperkeratosis, parakeratosis, and impaired epidermal barrier function. The skin is scaled, constricting bands encircle the tail and digits, the footpads are thickened and scaled, and loricrin staining is markedly reduced in the cornified layers and increased in the nucleus. Features of this phenotype, including nuclear loricrin localization and pseudoainhum (autoamputation), are characteristic of the Vohwinkel syndrome. We confirm that the phenotype develops in a loricrin-null genetic background, indicating that suppressed suprabasal AP1 factor function is sufficient to drive this disease. We also show that the phenotype regresses when suprabasal AP1 factor signaling is restored. Our findings suggest that suppression of AP1 factor signaling in the suprabasal epidermis is a key event in the pathogenesis of keratoderma.

Citing Articles

MOF-mediated histone H4 Lysine 16 acetylation governs mitochondrial and ciliary functions by controlling gene promoters.

Wang D, Li H, Chandel N, Dou Y, Yi R Nat Commun. 2023; 14(1):4404.

PMID: 37479688 PMC: 10362062. DOI: 10.1038/s41467-023-40108-0.

Mutations in PERP Cause Dominant and Recessive Keratoderma.

Duchatelet S, Boyden L, Ishida-Yamamoto A, Zhou J, Guibbal L, Hu R J Invest Dermatol. 2018; 139(2):380-390.

PMID: 30321533 PMC: 6586468. DOI: 10.1016/j.jid.2018.08.026.

Single Cell and Open Chromatin Analysis Reveals Molecular Origin of Epidermal Cells of the Skin.

Fan X, Wang D, Burgmaier J, Teng Y, Romano R, Sinha S Dev Cell. 2018; 47(1):21-37.e5.

PMID: 30220568 PMC: 6177292. DOI: 10.1016/j.devcel.2018.08.010.

Corneocyte proteomics: Applications to skin biology and dermatology.

Rice R, Durbin-Johnson B, Mann S, Salemi M, Urayama S, Rocke D Exp Dermatol. 2018; 27(8):931-938.

PMID: 30033667 PMC: 6415749. DOI: 10.1111/exd.13756.

Inactivation of DNase1L2 and DNase2 in keratinocytes suppresses DNA degradation during epidermal cornification and results in constitutive parakeratosis.

Fischer H, Buchberger M, Napirei M, Tschachler E, Eckhart L Sci Rep. 2017; 7(1):6433.

PMID: 28743926 PMC: 5527052. DOI: 10.1038/s41598-017-06652-8.

References

Scott C, Tattersall D, OToole E, Kelsell D . Connexins in epidermal homeostasis and skin disease. Biochim Biophys Acta. 2011; 1818(8):1952-61. DOI: 10.1016/j.bbamem.2011.09.004. View

Jang S, Steinert P . Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem. 2002; 277(44):42268-79. DOI: 10.1074/jbc.M205593200. View

ODriscoll J, Muston G, McGrath J, Lam H, Ashworth J, Christiano A . A recurrent mutation in the loricrin gene underlies the ichthyotic variant of Vohwinkel syndrome. Clin Exp Dermatol. 2002; 27(3):243-6. DOI: 10.1046/j.1365-2230.2002.01031.x. View

Ishida-Yamamoto A, McGrath J, Lam H, Iizuka H, Friedman R, Christiano A . The molecular pathology of progressive symmetric erythrokeratoderma: a frameshift mutation in the loricrin gene and perturbations in the cornified cell envelope. Am J Hum Genet. 1997; 61(3):581-9. PMC: 1715943. DOI: 10.1086/515518. View

Patel S, Zirwas M, English 3rd J . Acquired palmoplantar keratoderma. Am J Clin Dermatol. 2007; 8(1):1-11. DOI: 10.2165/00128071-200708010-00001. View

Efimova T, Deucher A, Kuroki T, Ohba M, Eckert R . Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets CCAAT/enhancer-binding protein alpha. J Biol Chem. 2002; 277(35):31753-60. DOI: 10.1074/jbc.M205098200. View

Crish J, Gopalakrishnan R, Bone F, Gilliam A, Eckert R . The distal and proximal regulatory regions of the involucrin gene promoter have distinct functions and are required for in vivo involucrin expression. J Invest Dermatol. 2005; 126(2):305-14. DOI: 10.1038/sj.jid.5700019. View

Rashid R, Cowan E, Abbasi S, Brieva J, Alam M . Destructive deformation of the digits with auto-amputation: a review of pseudo-ainhum. J Eur Acad Dermatol Venereol. 2007; 21(6):732-7. DOI: 10.1111/j.1468-3083.2007.02224.x. View

Young M, Li J, Rincon M, Flavell R, Sathyanarayana B, Hunziker R . Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A. 1999; 96(17):9827-32. PMC: 22295. DOI: 10.1073/pnas.96.17.9827. View

10.

Suga Y, Jarnik M, Attar P, Longley M, Bundman D, Steven A . Transgenic mice expressing a mutant form of loricrin reveal the molecular basis of the skin diseases, Vohwinkel syndrome and progressive symmetric erythrokeratoderma. J Cell Biol. 2000; 151(2):401-12. PMC: 2192631. DOI: 10.1083/jcb.151.2.401. View

11.

Drera B, Tadini G, Balbo F, Marchese L, Barlati S, Colombi M . De novo occurrence of the 730insG recurrent mutation in an Italian family with the ichthyotic variant of Vohwinkel syndrome, loricrin keratoderma. Clin Genet. 2007; 73(1):85-8. DOI: 10.1111/j.1399-0004.2007.00914.x. View

12.

Brown P, Chen T, Birrer M . Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994; 9(3):791-9. View

13.

Jaubert J, Patel S, Cheng J, Segre J . Tetracycline-regulated transactivators driven by the involucrin promoter to achieve epidermal conditional gene expression. J Invest Dermatol. 2004; 123(2):313-8. DOI: 10.1111/j.0022-202X.2004.23203.x. View

14.

Jarnik M, de Viragh P, Scharer E, Bundman D, Simon M, Roop D . Quasi-normal cornified cell envelopes in loricrin knockout mice imply the existence of a loricrin backup system. J Invest Dermatol. 2002; 118(1):102-9. DOI: 10.1046/j.0022-202x.2001.01661.x. View

15.

Rorke E, Adhikary G, Jans R, Crish J, Eckert R . AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation. Oncogene. 2010; 29(44):5873-82. PMC: 2974027. DOI: 10.1038/onc.2010.315. View

16.

Yoneda K, Hohl D, MCBRIDE O, Wang M, Cehrs K, Idler W . The human loricrin gene. J Biol Chem. 1992; 267(25):18060-6. View

17.

Young M, Farrell L, Lambert P, Awasthi P, Colburn N . Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun. Mol Carcinog. 2002; 34(2):72-7. DOI: 10.1002/mc.10050. View

18.

Adhikary G, Crish J, Lass J, Eckert R . Regulation of involucrin expression in normal human corneal epithelial cells: a role for activator protein one. Invest Ophthalmol Vis Sci. 2004; 45(4):1080-7. DOI: 10.1167/iovs.03-1180. View

19.

Amagai M, Stanley J . Desmoglein as a target in skin disease and beyond. J Invest Dermatol. 2011; 132(3 Pt 2):776-84. PMC: 3279627. DOI: 10.1038/jid.2011.390. View

20.

Ishida-Yamamoto A, Hohl D, Roop D, Iizuka H, Eady R . Loricrin immunoreactivity in human skin: localization to specific granules (L-granules) in acrosyringia. Arch Dermatol Res. 1993; 285(8):491-8. DOI: 10.1007/BF00376822. View